Researcher's Profile

TZUNG-DAU WANG (王宗道)

     ORCID Follow

Research Outline     

Dr. Wang's research interests are extensive and range from clinical research to biomedical research. He has been the global principal investigator for LCZ 696 2222 trial and local principal investigator for the GEMINI, TAO, ELIXA and RAVEL trials and co-investigator for RUTH, DISCOVERY, REACH, ACCORD and many more. Dr. Wang has been actively involved in biomedical research in a wide variety of areas like metabolic syndrome, insulin signalling, dyslipidemia, endothelial function, hypertension, coronary CT angiogram and has done extensive molecular and imaging studies on epicardial adipose tissue. He is the author of more than 100 international publications in Cardiology and Endocrinology fields including Circulation, Hypertension, Eur Heart J, J Clin Endocrinol Metab and Small and has been invited to speak at numerous local and international conferences and meetings. Not only a well-experienced clinical researcher, Dr. Wang is also experienced in various interventional cardiology treatments, with more than 4,000 cases of PCI performed till now. Dr. Wang is currently serving as the regional proctor of renal denervation therapy for resistant hypertension. He is also the pioneer in developing the interventional treatment for arteriogenic erectile dysfunction.

In addition, Dr. Wang is currently the secretary general of the Taiwan Hypertension Society and the deputy chairman of the Hypertension Committee of the Taiwan Society of Cardiology. He participated in the Writing Group of the 2010 Taiwan Hypertension Guidelines. He is also the Executive Editor of the Acta Cardiologica Sinica and has been an editorial board member of J Geriatric Cardiol and a reviewer for Hypertension, J Am Coll Cardiol, Am J Cardiol, Am J Hypertens, Atherosclerosis, and CJASN.